skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 23,098  for All Library Resources

Sorted by: Sorted by: Date-newestOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Journal Title: Business Wire remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Encouraging New Data Presented on Kite's Yescarta for Relapsed/Refractory Central Nervous System Lymphoma
Encouraging New Data Presented on Kite's Yescarta for Relapsed/Refractory Central Nervous System Lymphoma
Material Type:
Newspaper Article 		Add to My Research

Encouraging New Data Presented on Kite's Yescarta for Relapsed/Refractory Central Nervous System Lymphoma

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
2
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Material Type:
Newspaper Article 		Add to My Research

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
3
Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
Material Type:
Newspaper Article 		Add to My Research

Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
4
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
Material Type:
Newspaper Article 		Add to My Research

Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
5
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Material Type:
Newspaper Article 		Add to My Research

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
6
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO Annual Meeting
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO Annual Meeting
Material Type:
Newspaper Article 		Add to My Research

Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO Annual Meeting

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
7
Avanzanite Bioscience Reports AKANTIOR Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
Avanzanite Bioscience Reports AKANTIOR Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
Material Type:
Newspaper Article 		Add to My Research

Avanzanite Bioscience Reports AKANTIOR Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
8
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
Material Type:
Newspaper Article 		Add to My Research

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
9
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Material Type:
Newspaper Article 		Add to My Research

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
10
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushing's Syndrome Patients at ENDO 2024
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushing's Syndrome Patients at ENDO 2024
Material Type:
Newspaper Article 		Add to My Research

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushing's Syndrome Patients at ENDO 2024

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
11
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
Material Type:
Newspaper Article 		Add to My Research

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
12
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Material Type:
Newspaper Article 		Add to My Research

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Business Wire, 2024-06-02

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
13
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY (paliperidone palmitate)
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY (paliperidone palmitate)
Material Type:
Newspaper Article 		Add to My Research

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY (paliperidone palmitate)

Business Wire, 2024-06-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
14
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
Material Type:
Newspaper Article 		Add to My Research

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Business Wire, 2024-06-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
15
Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Material Type:
Newspaper Article 		Add to My Research

Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Business Wire, 2024-06-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
16
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Material Type:
Newspaper Article 		Add to My Research

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

Business Wire, 2024-06-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
17
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Material Type:
Newspaper Article 		Add to My Research

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Business Wire, 2024-06-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
18
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
Material Type:
Newspaper Article 		Add to My Research

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Business Wire, 2024-05-31

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
19
Gilead Provides Update on Phase 3 TROPiCS-04 Study
Gilead Provides Update on Phase 3 TROPiCS-04 Study
Material Type:
Newspaper Article 		Add to My Research

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Business Wire, 2024-05-30

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
20
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
Material Type:
Newspaper Article 		Add to My Research

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Business Wire, 2024-05-30

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by

Results 1 - 20 of 23,098  for All Library Resources

Sorted by: Sorted by: Date-newestOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1999  (67)
  2. 1999 To 2004  (287)
  3. 2005 To 2010  (2,270)
  4. 2011 To 2017  (8,574)
  5. After 2017  (11,901)
  6. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait